Wellington Management Group LLP Has $74.07 Million Stake in Immatics (NASDAQ:IMTX)

Wellington Management Group LLP increased its position in shares of Immatics (NASDAQ:IMTX) by 7.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 10,417,892 shares of the company’s stock after purchasing an additional 736,709 shares during the period. Wellington Management Group LLP owned approximately 8.73% of Immatics worth $74,071,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Quarry LP increased its position in Immatics by 29.4% during the 3rd quarter. Quarry LP now owns 11,000 shares of the company’s stock worth $126,000 after buying an additional 2,500 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in Immatics by 24.6% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 22,701 shares of the company’s stock worth $163,000 after acquiring an additional 4,477 shares during the period. Texas Capital Bank Wealth Management Services Inc acquired a new stake in Immatics in the 3rd quarter worth about $114,000. The Manufacturers Life Insurance Company boosted its holdings in Immatics by 9.3% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 164,766 shares of the company’s stock valued at $1,880,000 after purchasing an additional 13,997 shares during the period. Finally, State Street Corp grew its position in shares of Immatics by 11.2% during the 3rd quarter. State Street Corp now owns 225,202 shares of the company’s stock worth $2,570,000 after purchasing an additional 22,710 shares in the last quarter. 64.41% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of Immatics in a research report on Tuesday. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $16.67.

Immatics Stock Down 8.9 %

IMTX opened at $3.50 on Friday. The stock has a market capitalization of $417.75 million, a price-to-earnings ratio of -5.30 and a beta of 0.85. Immatics has a twelve month low of $3.39 and a twelve month high of $13.77. The company has a 50-day simple moving average of $4.81 and a 200 day simple moving average of $7.20.

Immatics (NASDAQ:IMTX) last posted its quarterly earnings results on Thursday, March 27th. The company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.51. Immatics had a negative net margin of 47.94% and a negative return on equity of 15.90%. The business had revenue of $15.67 million for the quarter, compared to analyst estimates of $16.16 million. Sell-side analysts anticipate that Immatics will post -0.72 EPS for the current fiscal year.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.